1.Functional Cyspepsia.
Journal of the Korean Medical Association 2005;48(1):48-60
No abstract available.
Helicobacter pylori
2.Efficacy of helicobacter pylori eradication as an upfront treatment of secondary immune thrombocytopenia: an experience from Pakistan
Sadia Sultan ; Mohammed Irfan ; Jamaluddin Kakar ; Miray Hasan
The Medical Journal of Malaysia 2016;71(2):53-56
Background: The effect of Helicobacter-pylori eradication
therapy on the platelet counts in patients with immune
thrombocytopenia is still debatable. The aim of this study
was to assess the response rates of standard triple
eradication therapy in secondary immune thrombocytopenia
with Helicobacter pylori infection.
Methods: From January 2012 to December 2013, 197
patients were diagnosed to have immune thrombocytopenia,
out of which 22(11.1%) patients infected with HelicobacterPylorus
were enrolled in this study. Helicobacter-Pylori
infection was documented by Helicobacter-pylori stool
antigen enzyme immunoassay method. All positive patients
were put on triple eradication therapy. The responses rates
to treatment were defined as per International Working
Group on ITP.
Results: Mean age of patients was 43.18±12.5 years. There
were 10(45.5%) males and 12 (54.5%) females. Of the 22
patients, 7(31.8%) exhibited a complete response (CR) to Hpylori
eradication therapy; 10(45.4%) attained a response;
and 5(22.7%) had no response. Mean base line platelet
counts were 53.36±24.5x109
/l, while platelet counts at 4 week
following eradication was 80.86±51.0x109
/l (P=0.003). The
predictive factor of response following eradication therapy
was baseline platelet counts. Virtually all responders had
baseline platelet counts >30x109
/l and all non-responders
had <30x109
/l of platelet counts.
Conclusions: Though the prevalence of H-pylori is low, this
study confirmed the efficacy of eradication in increasing the
platelet counts in H-pylori positive patients with ITP. It is an
important measure in short time, safe and very cost effective
to achieve platelets increment. We endorse the routine
detection and eradication treatment of H-pylori infective ITP
patients.
Helicobacter pylori
3.PCR-based analysis of Helicobacter pylori virulent genotypes among dyspeptic patients from Chittagong, Bangladesh
Abdul Musaweer Habib ; Md. Jibran Alam ; Bashudev Rudra ; Dil Umme Salma Chowdhury ; Md Abdul Quader ; Mohammad Al-Forkan
Malaysian Journal of Microbiology 2017;13(1):xx-xx
Aims: Helicobacter pylori is a causative agent of gastroduodenal diseases in Bangladesh as well as throughout the
world. This study aimed to determine the H. pylori cagA, vacA and iceA virulent genotypes by PCR directly in gastric
biopsies from dyspeptic patients of Chittagong, Bangladesh and evaluating the association of these genotypes with
clinical manifestations.
Methodology and results: CLO (Campylobacter-Like Organism) test and Hp16s PCR (16S rRNA based H. pylori
specific PCR) was performed to confirm H. pylori infection. Among 111 patients, H. pylori infection was found in 60
patients by CLO test, while Hp16s PCR revealed that 54 patients were H. pylori positive. PCR amplification of the H.
pylori virulence genes was successful in 35 gastric biopsies amongst the 54 Hp16s PCR positive biopsies. The positive
rates for the cagA, vacAs1, vacAs2, vacAm1, vacAm2, iceA1, iceA2 genes were 34.3%, 71.4%, 8.6%, 62.9%, 28.6%,
20% and 11.4%, respectively. The allelic variant vacAs1m1 had a predominant percentage with 51.4%, followed by
vacAs1m2, vacAs2m2 and vacAs1m1m2 with 14.3%, 5.7% and 2.9%, respectively. Among the subtypes of vacAs1, only
s1a was detected in 54.3% of biopsies while none of the cases showed the s1b and s1c genotypes. However, there was
no statistically significant association (p>0.05) observed between the virulent genotypes and clinical conditions.
Conclusion, significance and impact of study: We found that cagA, vacAs1m1 and iceA1 were the most frequent H.
pylori genotypes in severe clinical outcomes of the infection. The data in this study would provide a basis for
understanding the diverse virulence pattern of this bacterium in Bangladeshi dyspeptic patients.
Helicobacter pylori
4.Prevalence of Helicobacter Pylori Infection among Patients Attending Gastroenterology Endoscopy Unit at Serdang Hospital
Chieng Jin Yu ; Pan Yan ; Loong Yik Yee
Malaysian Journal of Medicine and Health Sciences 2015;11(1):11-17
To study the prevalence of Helicobacter Pylori (H. pylori) infection, according to ethnicity, gender and
endoscopic findings among the patients underwent the oesophago-gastro-duodenoscopes (OGDS) at
gastroenterology endoscopy unit, Hospital Serdang, Selangor, Malaysia. The database of all whom
underwent OGDS at the gastroenterology endoscopy unit, Hospital Serdang from 1st August 2010
to 31st July 2012 was collected and assessed, retrospectively. A total of 924 patients who underwent
OGDS were analyzed for the H. pylori infection by using Campylobacter-like organism (CLO) test. 130
(14.07%) tested positive, and their data were further studied according to gender, ethnicity, age group,
initial indication for OGDS and endoscopic finding. The prevalence rate among males was 15.15%
(70/462), while it was 12.99% (60/462) among females. In terms of ethnics, H. pylori infection was
commonly found among Indian and Chinese with prevalence rate of 25.13% (50/199) and 17.41%
(51/293) respectively. These figures are significantly higher than the 6.01% (25/416) for Malays. The
age group (31-50 years old) had the highest prevalence rate of H. Pylori infection, which is of 18.55%
(41/221). No significant difference was observed among initial indications for OGDS. Erosions were the
commonest finding in H. pylori positive group with rate of 51.54% (67/130). However, erosions were
not uncommon in H. pylori negative group as well with the rate of 48.61% (386/794). H. pylori infection
rate among Malaysians was generally low, with the highest rate in Indians, followed by Chinese and
relatively low in Malays. No significant difference between the prevalence rate of H. pylori infection
in male and that in female was found. Erosions were equally common in either H. pylori positive or H.
pylori negative group.
.
Helicobacter pylori
5.Success rate of helicobacter pylori eradication using vonoprazan-based triple therapy as first-line treatment at a tertiary hospital in Baguio City
Tristan John B. Guston, MD ; Maria Elizabeth T. Espiritu, MD
Philippine Journal of Internal Medicine 2023;61(2):36-44
Background:
Helicobacter pylori is acknowledged to cause chronic gastritis and peptic ulcer disease and is also implicated
in gastric carcinoma and B cell mucosa-associated lymphoid tissue (MALT) lymphoma development. It has infected at least
half of the world’s population. Proton Pump Inhibitors (PPIs) have been the conventional antacid of choice for H. pylori
eradication triple therapy, while vonoprazan is a novel drug of its class that was recently studied but is limited to an oral
form which makes it less feasible in cases of acute gastrointestinal bleeding. According to several systematic reviews and
meta-analyses, the vonoprazan-based triple therapy regimen for H. pylori eradication is a non-inferior treatment to
traditional PPI-based treatment when given in 1 week for patients having no active gastrointestinal bleeding. Likewise, a
safety profile has been established with its use, offering an alternative treatment option.
Objectives:
The research aims to identify the H. pylori eradication rate among H. pylori-positive patients who received a
vonoprazan-based triple therapy regimen as outpatients, describe their clinicodemographic profile, and identify potential
side effects associated with the treatment.
Methods:
This study utilized a cross-sectional study design in a single tertiary institution from January 2018 to December
2020. Descriptive and inferential statistics were used in data analysis. Frequency and percentage were utilized to determine
the success and failure rates of H. pylori eradication, describe the clinicodemographic profile of patients who underwent
vonoprazan-based triple therapy, and the potential side effects with treatment. The chi-square test of independence was
applied to assess the significant difference in the successful and failed eradication rates across the clinicodemographic
profile. A P-value of <0.05 was considered statistically significant, and statistical analyses were conducted using SPSS
version 20.0.
Results:
32 (91%) had successful H. pylori eradication, with the majority of them determined by a negative 13C-UBT result
(62.8%) and the rest with a negative H. pylori stool antigen test (28.6%). The majority of patients undergoing H. pylori
eradication using a vonoprazan-based regimen with documented successful eradication belonged to the 19 to 39 years
old group (50%), clerical support workers (40.63%), with a chief complaint of abdominal pain (46.88%), with no known co-
morbid illness (75%), and with endoscopic finding limited to antral gastritis alone (46.88%). This study described only two
documented side effects of treatment: diarrhea and abdominal pain (2.9%).
Conclusion
Vonoprazan-based triple therapy, given at 20 mg twice daily for 7 days, has shown a high H. pylori eradication
rate among hemodynamically stable patients, without active bleeding, and treated on an outpatient basis. There was a
significant difference in eradication success and failure across co-morbidities, with a higher success rate in those without
co-morbid illness. A high success rate was also seen in patients <40 years of age, with a single chief complaint, and with
antral gastritis as the sole endoscopic finding.
Helicobacter pylori
6.Clinical Significance of Helicobacter pylori Infection.
Journal of the Korean Academy of Family Medicine 2003;24(4):321-327
No abstract available.
Helicobacter pylori*
;
Helicobacter*
7.Helicobacter pylori infection and COX-2.
Korean Journal of Medicine 2002;62(2):125-127
No abstract available.
Helicobacter pylori*
;
Helicobacter*
8.Helicobacter pylori infection and COX-2.
Korean Journal of Medicine 2002;62(2):125-127
No abstract available.
Helicobacter pylori*
;
Helicobacter*
9.Antimicrobial Resistance of Helicobacter pylori.
Korean Journal of Clinical Microbiology 2001;4(2):73-77
No abstract available.
Helicobacter pylori*
;
Helicobacter*